Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563551 | 1.00 | APOBEC3G (0.48) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| SCHEMBL31203 | 0.91 | TDP1 (0.55) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| SCHEMBL29534868 | 0.91 | TDP1 (0.55) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| SCHEMBL29366632 | 0.85 | APOBEC3G (0.60) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| SCHEMBL41139 | 0.85 | APOBEC3G (0.60) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| SCHEMBL27292 | 0.84 | CYP4F2 (0.49) | APOBEC3GTDP1CYP4F2CYP4A11TAAR1 | |
| Tetrahydrofuran SCHEMBL4655531 | 0.82 | CYP4F2 (0.40) | APOBEC3GTDP1CYP4F2CYP4A11TSHR | |
| SCHEMBL43837 | 0.81 | TAAR1 (0.62) | TDP1TAAR1TSHRHSPA5MPO | |
| SCHEMBL29646276 | 0.81 | TAAR1 (0.62) | TDP1TAAR1TSHRHSPA5MPO | |
| Hydrochloric Acid SCHEMBL28375849 | 0.79 | APOBEC3G (0.55) | APOBEC3GCYP4F2CYP4A11TAAR1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880688-B | Synthesis method of diol | 温州大学新材料与产业技术研究院 | 2023-09-08 | — | — | CN | disclosed |
| CN-113880688-A | Method for synthesizing diol | 温州大学新材料与产业技术研究院 | 2022-01-04 | — | — | CN | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108610237-B | Method for synthesizing o-xylene glycol derivative | 复旦大学 | 2021-07-23 | — | — | CN | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| EP-2044251-B1 | BIODEGRADABLE ALIPHATIC POLYESTER FOR USE IN NONWOVEN WEBS | NATUREWORKS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-4213972-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213974-A | ANTIBACTERIAL | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4188319-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1980-02-12 | — | — | US | disclosed |
| US-4183920-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1980-01-15 | — | — | US | disclosed |
| US-4174312-A | ACYLATION, HYDROLYSIS, SALT FORMATION, CATALYTIC HYDROGENATION | ABBOTT LABORATORIES (US) | 1979-11-13 | — | — | US | disclosed |
| US-4173564-A | 4-N-acylfortimicin B derivatives and the chemical conversion of fortimicin B to fortimicin A | ABBOTT LABORATORIES (US) | 1979-11-06 | — | — | US | disclosed |
| US-4155902-A | ACYLATION, HYDROGENOLYSIS | ABBOTT LABORATORIES (US) | 1979-05-22 | — | — | US | disclosed |
| US-4147711-A | Ethylenic silicon compounds and thermoplastic elastomers obtained therefrom | RHONE-POULENC INDUSTRIES (FR) | 1979-04-03 | — | — | US | disclosed |
| US-4091032-A | ANTIMICROBIAL AGENTS | ABBOTT LABORATORIES (US) | 1978-05-23 | — | — | US | disclosed |
| US-4088670-A | P-(DIMETHYLVINYLSILYL-METHOXY)-BENZOYL CHLORIDE FROM DIMETHYLVINYL-CHLOROMETHYLSILANE AND A P-HYDROXYBENZOIC ACID | RHONE-POULENC INDUSTRIES (FR) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | APOBEC3G 234/4885TDP1 495/4885CYP4F2 4145/4885 |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | APOBEC3G 2279/4885TDP1 1156/4885CYP4F2 825/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | APOBEC3G 3611/4885TDP1 637/4885CYP4F2 847/4885 |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | APOBEC3G 2279/4885TDP1 1156/4885CYP4F2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.